Investigational Drug Details
| Drug ID: | D003 |
| Drug Name: | Acipimox |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | DB09055 |
| DrugBank Description: | Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout. |
| PubChem ID: | 5310993 |
| CasNo: | 51037-30-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | C(=O)(O)c1cn(=O)c(cn1)C |
| Structure: |
|
| InChiKey: | DJQOOSBJCLSSEY-UHFFFAOYSA-N |
| Molecular Weight: | 154.125 |
| DrugBank Targets: | -- |
| DrugBank MoA: | Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | Used in the treatment of hyperlipidemias (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood). |
| Targets: | ADA inhibitor; TAG modulator |
| Therapeutic Category: | Hypolipidemic drug |
| Clinical Trial Progress: | Clinical trial on-going (ChiCTR-IPR-17012342) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0235 | ChiCTR-IPR-17012342 | Post-market | Not Recruiting | No Results Available | 11/08/2017 | 21 August 2017 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A18925 | 26868515 | Lipids Health Dis | Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats. | Details |
| A42932 | 33045621 | Redox Biol | Homocysteine promotes hepatic steatosis by activating the adipocyte lipolysis in a HIF1α-ERO1α-dependent oxidative stress manner. | Details |
| A45465 | 24424058 | Endocrinology | Nicotine in combination with a high-fat diet causes intramyocellular mitochondrial abnormalities in male mice. | Details |
| A45722 | 23093702 | Endocrinology | Additive effects of nicotine and high-fat diet on hepatic steatosis in male mice. | Details |
| A52172 | 30429322 | Proc Natl Acad Sci U S A | Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. | Details |